| Literature DB >> 30423406 |
Xianzhou Song1, Hui Chen1, Chengwei Zhang1, Yang Yu2, Zhongyuan Chen3, Han Liang4, George Van Buren5, Amy L McElhany5, William E Fisher5, David M Lonard6, Bert W O'Malley7, Jin Wang8.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant and lethal disease with few treatment options. Steroid receptor coactivator-3 (SRC-3, also known as NCOA3, AIB1, pCIP, ACTR, RAC3, TRAM1) sits at the nexus of many growth signaling pathways and has been pursued as a therapeutic target for breast, prostate and lung cancers. In this study, we find that SRC-3 is overexpressed in PDAC and inversely correlates with patient overall survival. Knockdown of SRC-3 reduces pancreatic cancer cell proliferation, migration and invasion in vitro. Additionally, inhibition of SRC-3 using either shRNA or a small molecule inhibitor can significantly inhibit tumor growth in orthotopic pancreatic cancer mouse models. Collectively, this study establishes SRC-3 as a promising therapeutic target for pancreatic cancer treatment.Entities:
Keywords: Pancreatic ductal adenocarcinoma; Small molecule inhibitor; Steroid receptor coactivator
Mesh：
Substances：
Year: 2018 PMID： 30423406 PMCID： PMC6311429 DOI： 10.1016/j.canlet.2018.11.012
Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679